EVMN Evommune, Inc.

BEARISH Impact: 5/10 144
Horizon days Filed May 28, 2026 Processed 9d 20h ago SEC 0001950047-26-005228
Form 144 — notice of proposed sale of securities
Latest settled — T+5d
EVMN ▼ -14.25% at T+5d
SHORT call ✓ call won +14.25% · α vs SPY +11.75% · entry $23.23 → $19.92
Next anchor: T+20d in 11d
Last close $19.83 (close Jun 12) · +14.64% from $23.23 entry (call sign-flipped)
Entry anchored
May 28, 03:59 PM ET
via Databento tick
T+1d
-4.56%
call +4.56% · α +4.82%
$22.17
settled 17d ago
T+5d
-14.25%
call +14.25% · α +11.75%
$19.92
settled 11d ago
T+20d
call — · α —
in 11d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Gregory S. Moss, an officer of Evommune, filed a Form 144 on May 28, 2026, indicating intent to sell 14,223 shares of common stock valued at approximately $331,965. The shares were acquired through the exercise of stock options on the same day, and the sale is planned for the open market via Morgan Stanley. This insider sale follows three other insider sales totaling $871K over the past 30 days, creating a pattern of insider selling at a company with a $745M market cap and strong analyst consensus.

Actionable Insight

The pattern of multiple insider sales (4 in 30 days) at a pre-revenue biotech with strong analyst coverage is a cautionary signal. Monitor for additional Form 144 or Form 4 filings from other insiders. The stock has shown negative momentum (avg -14% T+20 on prior reports), suggesting the market may already be pricing in insider de-risking ahead of clinical catalysts.

Key Facts

  • Officer Gregory S. Moss filed Form 144 to sell 14,223 shares of common stock.
  • Proposed sale value is approximately $331,965 based on filing date price.
  • Shares were acquired via exercise of stock options on the same day (May 28, 2026).
  • Sale is planned for open market execution through Morgan Stanley.
  • This is the 4th insider sale in the last 30 days, totaling over $1.2M in proposed/actual insider selling.
  • Company has a $745M market cap with 94% analyst bullish rating (16 Buy, 1 Hold).

Financial Impact

Proposed sale of $331,965 by an officer, representing approximately 0.04% of market cap.

insider sellingdilution

Risk Factors

  • Insider selling pattern may indicate lack of confidence ahead of clinical data readouts.
  • Stock has underperformed significantly (avg -14% T+20 on prior reports), suggesting persistent selling pressure.
  • Pre-revenue biotech with high cash burn — insider sales could signal concerns about runway or pipeline progress.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005228
Document: 0001950047-26-005228-index.html0001950047-26-005228
Document: 0001950047-26-005228.txt0001950047-26-005228
9 reports for EVMN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for EVMN — sortable, filterable
Type Now
Jun 4, 2026
11d ago
Insider Cluster
BEARISH ★ 5/10
$20.69 $19.92▲ +3.72%▲ +1.12%$19.83 (+4.16%)
Jun 2, 2026
12d ago
144
NEUTRAL ★ 3/10
$19.73 $20.69▲ +4.87%▲ +4.47%$19.83 (+0.51%)
Jun 2, 2026
13d ago
Insider Cluster
NEUTRAL ★ 3/10
$19.82 $19.73▼ −0.45%▲ +0.27%$19.83 (+0.05%)
May 28, 2026
17d ago
144
BEARISH ★ 5/10
$23.23 $22.17▲ +4.56%▲ +4.82%$19.83 (+14.64%)
Apr 27, 2026
7w ago
EFFECT
NEUTRAL ★ 4/10
$25.00 $25.58▲ +2.32%▲ +2.81%$19.83 (−20.68%)
Apr 21, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$27.12 $25.84▼ −4.72%▼ −4.33%$19.83 (−26.88%)
Apr 17, 2026
8w ago
S-1
NEUTRAL ★ 4/10
$27.97 $28.07▲ +0.36%▲ +1.01%$19.83 (−29.10%)
Apr 13, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$26.63 $26.94▲ +1.16%▲ +0.39%$19.83 (−25.54%)
Mar 5, 2026
14w ago
8-K
BULLISH ★ 8/10
$26.50 $24.61▼ −7.13%▼ −7.98%$19.83 (−25.17%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 4h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access